PROCEPT BioRobotics (NASDAQ: PRCT) shares Q3 2025 results via 8-K

Rhea-AI Filing Summary

PROCEPT BioRobotics Corporation filed a current report stating that it issued a press release announcing its financial results for the quarter ended September 30, 2025. The company used this report to make investors aware of the new earnings release without having the detailed numbers directly in the filing.

The press release, dated November 4, 2025, is attached as Exhibit 99.1 and is incorporated by reference, but is furnished rather than filed, which limits certain legal liabilities under securities laws. The company also included a cover page interactive data file in Inline XBRL format as Exhibit 104 to support electronic reporting and data analysis.

0001588978false00015889782025-11-042025-11-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 4, 2025

PROCEPT BIOROBOTICS CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

001-40797

26-0199180

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification Number)

150 Baytech Drive

San Jose, California 95134

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (650) 232-7200

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.00001 par value per share

PRCT

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 2.02 Results of Operations and Financial Condition

On November 4, 2025, PROCEPT BioRobotics Corporation (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.						Description
99.1						Press Release of PROCEPT BioRobotics Corporation, dated November 4, 2025
104						Cover Page Interactive Data File, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						PROCEPT BIOROBOTICS CORPORATION
Date: November 4, 2025						By:			/s/ Alaleh Nouri
									Alaleh Nouri
									Chief Legal Officer and Secretary

FAQ

What did PROCEPT BioRobotics (PRCT) report in this 8-K?

PROCEPT BioRobotics reported that it issued a press release announcing its financial results for the quarter ended September 30, 2025, and furnished that press release as an exhibit.

Which period do the PROCEPT BioRobotics (PRCT) results cover?

The results discussed in the press release and referenced in this report cover the quarter ended September 30, 2025.

Where can investors find the detailed Q3 2025 results for PROCEPT BioRobotics?

The detailed quarterly results are contained in the press release furnished as Exhibit 99.1 to this report and incorporated by reference.

Is the PROCEPT BioRobotics earnings press release considered filed with the SEC?

No. The report specifies that the information in it, including Exhibit 99.1, is furnished and not deemed filed for purposes of Section 18 of the Exchange Act.

What exhibits are included with this PROCEPT BioRobotics 8-K?

The report includes Exhibit 99.1, a press release dated November 4, 2025, and Exhibit 104, the cover page interactive data file in Inline XBRL format.

Who signed this PROCEPT BioRobotics 8-K on behalf of the company?

The report was signed on behalf of PROCEPT BioRobotics Corporation by Alaleh Nouri, Chief Legal Officer and Secretary.